Ronald Evans

Ronald M.
Evans is the founder of Ligand Pharmaceuticals, Inc. (1987), Syndax Pharmaceuticals, Inc. (2005), Synchronicity Pharma, Inc. (2008), Mitobridge, Inc. (2013), and Metacrine, Inc. (2014).
He is also the founder of Xenopharm, Inc., X-Ceptor Therapeutics, Inc., XTuit Pharmaceuticals, Inc. Dr. Evans's current jobs include Director & Professor at The Salk Institute for Biological Studies, Director at American Association for Cancer Research, Member at National Academy of Sciences, Member at American Academy of Arts & Sciences, and Member at National Academy of Medicine (United States).
Dr. Evans received his doctorate degree from the University of California, Los Angeles in 1974 and his undergraduate degree from the same university in 1970.